Variants of human ciliary neurotrophic factor (hCNTF)

Details Variants of human ciliary neurotrophic factor (hCNTF) Variants of human ciliary neurotrophic factor (hCNTF)

1999-07-06

2004-06-29

Kunz, Gary (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S399000, C930S120000

Reexamination Certificate

active

06756357

ABSTRACT:

This application is the National Stage of International Application No. PCT/IT97/00163, filed Jul. 10, 1997.
FIELD OF THE INVENTION
The present invention relates to the field of neurology. Subject of the invention are mutants of the human ciliary neurotrophic factor (hCNTF) that show a range of action different from that of the wild-type molecule. These variants are characterised by the fact that they have a strongly reduced ability to interact with the LIF receptor (LIFR). As a consequence they have an extremely reduced biological activity on the majority of cells responding to CNTF. However, they retain a high biological activity on certain neurone cells, probably because the latter express large amounts of LIFR and/or CNTF receptor &agr; (CNTFR&agr;) bound to the membrane. This property can be used to reduce the peripheral side effects resulting from administration of CNTF.
BACKGROUND OF THE INVENTION
The human ciliary neurotrophic factor (hCNTF) is a neurocytokine of 23 kDa. It is expressed in Schwann cells and astrocytes, and exerts potent stimulatory effects on the survival and differentiation of a variety of neuronal and glial cells (both in vitro and in vivo), including motor neurons sensor neurons, sympathetic neurons, neurons of the hippocampus and oligodendrocytes (1, 2). The physiological role of CNTF would appear to be that of acting as a factor involved in the prevention of neuronal degeneration following injury (2). This protective action, which CNTF has shown in vivo on many nerve cells, has given hopes for its clinical application in the treatment of human neurodegenerative diseases (3).
As well as its neuroprotective action, however, it has been seen that CNTF also elicits in vivo a wide variety of effects, consisting of loss of weight and anorexia, acute-phase response and fever. There is therefore a problem with the pharmacological use of CNTF because of these side effects.
Like other growth factors, and in particular cytokines, CNTF exerts its actions through the binding, sequential assembly, and activation of a multisubunit receptor complex (4, 5). The receptor complex of which CNTF forms a part is made up of six subunits (similarly to the case of interleukin 6) (6). The complex is made up of two CNTF molecules, two &agr;-receptor specific molecules forming a low-affinity bond with CNTF (CNTFR&agr;) and two signal transducing subunits (LIFR and gp130) (11). The CNTF sites involved in binding with gp130and with the specific receptor can be identified by analogy to interleukin 6 (7, 8, 10). The bonding site for CNTF and the LIF receptor (LIFR) has not yet been identified.
Multiple alignment of human, rabbit, rat and mouse CNTF sequences with other cytokine sequences that bind the LIF receptor (such as LIF, oncostatin M and CT-1) reveals the presence of two conserved amino residues within the structural motif known as D1. The two amino acids are phenylalanine in position 152 and lysine in position 155. As will be shown in greater detail in the following examples, the two amino acids form part of the LIFR bonding site. On the basis of this notion, CNTF mutants were generated in which the two amino acids were replaced by alanine, and the sequences of both the wild-type molecule (SEQ ID NO:1) and the mutants which are the object of the present invention are given in table 1 (for the sake of simplicity the whole amino acid sequence is not given, only the amino acid positions from 152 to 167). Although the literature indicates that one of the two mutants (Lys155Ala/CNTF) is completely inactive on hen neurons (10), the biological activity of both mutants was evaluated, and it was demonstrated that, contrary to previous reports (10), they act as powerful agonists on the membrane receptor of certain neuronal cells, whereas their biological activity is strongly reduced when they are bound to the LIF receptor or to the soluble CNTF receptor. A possible interpretation of this phenomenon may be the following: as the biological effects of these molecules depend on the concentrations of CNTFR&agr; and LIF receptor, they are amplified when the local receptor concentration is very high, as is the case in receptors that are bound to the cell membrane of certain neuronal cell populations.
TABLE 1
SEQ
ID
Amino acid
NO:
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
1
Phe
Glu
Lys
Lys
Leu
Trp
Gly
Leu
Lys
Val
Leu
Gln
Glu
Leu
Ser
Gln
(hCNTF)
2
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Asp
His
(MUT-DH)
3
Ala
.
.
.
.
.
.
.
.
.
.
.
.
.
Asp
His
(Phe152Ala/MUT-DH)
4
.
.
.
Ala
.
.
.
.
.
.
.
.
.
.
Asp
His
(Lys155Ala/MUT-DH)
5
Ala
.
.
Ala
.
.
.
.
.
.
.
.
.
.
.
.
(Phe152Ala/Lys155Ala/
hCNTF)
6
.
.
.
Ala
.
.
.
.
.
.
.
.
.
.
.
.
(Lys155Ala/CNTF)
7
Ala
.
.
Ala
.
.
.
.
.
.
.
.
.
.
Asp
His
(Phe152Ala/Lys155Ala/
MUT-DH)
The discovery that these molecules exert a biological activity on neuronal cells expressing membrane-bound receptors and that on the contrary they show an extremely weak biological activity when interacting with the soluble receptor indicates that molecules that are modified in the positions indicated can be used for specific reaction with neuronal cells without causing peripheral side effects mediated by the soluble receptor bond.
Subject of the present invention are therefore variants of the human ciliary neurotrophic factor (hCNTF), characterised by replacement of the phenylalanine 152 and/or of the lysine 155 with alanine and comprising in particular an amino acid sequence chosen from the sequences indicated in SEQ ID NO:3 to SEQ ID NO:7.
The molecules represented by SEQ ID NO: 3 to SEQ ID NO:6 have a reduced ability to bond to the LIF receptor and to activate it by means of soluble CNTFR&agr;, and on the contrary act as agonists on the CNTFR of certain neuronal cells. The molecule represented by SEQ ID NO:7 acts as a competitive antagonist for the CNTFR&agr; receptor bond.
The present invention also extends to pharmaceutical preparations making use of these molecules for treatment of diseases or pathologies of the nervous system, or of other pathologies involving cells that respond to CNTF, including diseases or pathologies of the nervous system that cause damage to the nervous system itself.
Table 2 shows the data relating to CNTFR&agr; receptor binding activities of the various mutants of CNTF. The concentration of protein needed to inhibit by 50% (IC50) the binding of biotinylated CNTF or biotinylated MUT-DH to immobilised CNTFR&agr; was determined. Relative binding is the ratio (IC50 of CNTF)/(IC50 of tested protein).
TABLE 2
Protein
Relative Binding
SEQ ID NO:1
1.0
SEQ ID NO:2
41 ± 4 
SEQ ID NO:3
32 ± 11
SEQ ID NO:4
42 ± 2 
SEQ ID NO:5
0.9 ± 0.1
SEQ ID NO:6
1.0 ± 0.1
SEQ ID NO:7
51 ± 19


REFERENCES:
patent: 5939534 (1999-08-01), Inoue et al.
patent: WO 94/09134 (1994-04-01), None
patent: WO 96/01319 (1996-01-01), None
Jackowski: British J. Neurosurgery 9: 303-317, 1995.*
Rudinger, In “Peptide Hormones” (ed. J.A. Parsons) University Park Press, Baltimore, pp. 1-7, 1976.*
Barinaga Science 264: 772-774, 1994.*
Di Marco, Annalise et al., “Identification of ciliary neurotrophic factor (CNTF) residues essential for leukemia inhibitory factor receptor binding and generation of CNTF receptor antagonists.”, Proc. Natl. Acad. Sci. USA., vol. 93, pp. 9247-9252 (1996).
Panayotatos, Nikos et al., “Exchange of a single amino acid interconverts the specific activity and gel mobility of human and rat ciliary neurotrophic factors.”, The Journal of Biological Chemistry, vol. 268, No. 25, pp. 1900-19003 (1993).
Saggio, Isabella et al., “CNTF variants with increased biological potency and receptor selectivity define a functional site of receptor interaction.”, The EMBO Journal, vol. 14, No. 13, pp. 3045-3054 (1995).

Affiliated with

Also associated with

Rating

Variants of human ciliary neurotrophic factor (hCNTF) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Variants of human ciliary neurotrophic factor (hCNTF), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of human ciliary neurotrophic factor (hCNTF) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3357109